Efficacy of Psychological Therapy in Chronic Pain and Fibromyalgia
DOLORTRATPSI
Efficacy of Mindfulness-based Pain Management in Patients With Chronic Pain With and Without Fibromyalgia
1 other identifier
interventional
112
1 country
1
Brief Summary
Today, one of the most important challenges of the health system is the attitude towards chronic disorders. That implies changing from a health structure established for the treatment of acute diseases to a continued care system. In this sense, the approach of chronic pain, of non-oncological origin, supposes an important care challenge, to which this project wishes to respond. Chronic pain affects one of every Europeans (19%), and has a prevalence of 11% in Spain, being one of the most important causes of medical consultation and is associated with high personal, social and economic costs. For example, in 2017 it was calculated that it has an economic impact of between 1.7 and 2.1% of Spain's GDP. Referred to the psychological consequences of the disease, it has been found that 42% of people who have chronic pain suffer insomnia, a 40% anxiety, and 24% depressive symptoms. Hence the importance of implementing evidence-based psychological treatments along with their treatment as usual The main objective is comparing the efficacy of mindfulness-based pain management (MBPM), together with the usual medical treatment, in patients diagnosed with chronic pain, with and without comorbid fibromyalgia. Specific objectives are:
- 1.To study the sociodemographic and clinical profile of patients with chronic pain, with and without fibromyalgia.
- 2.Define the characteristics of patients who are in the different stages of the disease: stage 1 (less than two years since diagnosis); stage 2 (between 2 and 4 years); stage 3 (between 5 and 8 years), and stage 4 (more than 8 years).
- 3.Check the effectiveness of psychological therapies MBPM depending on the presence of fibromyalgia.
- 4.Check the effectiveness of the psychological treatment in function of the stage of the disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2019
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2019
CompletedFirst Submitted
Initial submission to the registry
June 14, 2019
CompletedFirst Posted
Study publicly available on registry
June 20, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2021
CompletedMarch 16, 2022
March 1, 2022
1.7 years
June 14, 2019
March 1, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Lattinen Index- IL
It is a scale with five items to assess variables associated with pain: frequency, intensity, disability, drugs usage and sleep problems. These are assessed by a Likert scale of 0 to 4, in order to explain the discomfort that pain generates. (Gonzalez-Escada, 2012)
base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41)
Secondary Outcomes (8)
Change in the Fibromyalgia Impact Questionnaire- FIQ
base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41)
Change in the Listado de Sintomas Breve- LSB-50
base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41)
Change in the Short Form 12 Health Survey- SF-12
base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41)
Change in Cuestionario de afrontamiento del dolor- CAD-R
base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41)
Change in Connor-Davison Resilience Scale- CDRISC
base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41)
- +3 more secondary outcomes
Other Outcomes (1)
Client Satisfaction Questionnaire
end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41)
Study Arms (2)
control group
OTHERThe patients received usual medical care.
MBPM- Minfulness- Based Pain Management
EXPERIMENTALPsychological intervention with 8 group sessions ( 8 -10 subjects) with a duration of 2 and a half hours per session and a weekly periodicity (total hours 1080). It is centered on training on the awareness of physical, cognitive and emotional sensations, and the attentional processes to become an observer of one's own thoughts and emotions. With the aim to provide greater flexibility to manage pain
Interventions
8 group session of maindfulness-based treatment to management pain
Eligibility Criteria
You may qualify if:
- Be able to complete the assessment protocol
- Suffer from chronic non-oncological pain, lasting longer than 6 months
- Not being receiving psychological treatment
- Sign the informed consent
You may not qualify if:
- Present a cognitive impairment, such as a dementia
- Present a diagnosis of a psychotic disease, bipolar disease or additive disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Basque Country
San Sebastián, Guipuzcoa, 20018, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Karmele Salaberria, PH.D
University of Basque Country
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- PhD. Lecturer in Psychology
Study Record Dates
First Submitted
June 14, 2019
First Posted
June 20, 2019
Study Start
June 1, 2019
Primary Completion
January 30, 2021
Study Completion
June 30, 2021
Last Updated
March 16, 2022
Record last verified: 2022-03